BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Friedlaender, Alex; Vuilleumier, Aurélie; Viassolo, Valeria; Ayme, Aurélie; De Talhouet, Solène; Combes, Jean-Damien; Peron, Julien; Bodmer, Alexandre; Giraud, Sophie; Buisson, Adrien; Bonadona, Valerie; Gauchat-Bouchardy, Isabelle; Tredan, Olivier; Chappuis, Pierre O; Labidi-Galy, S Intidhar.
Breast Cancer Res Treat
; 174(3): 775-783, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30635808
Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.
Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study.
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial.
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.
The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.
A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.